Rebecca G Levin-Epstein, Naomi Y Jiang, Xiaoyan Wang, Shrinivasa K Upadhyaya, Sean P Collins, Simeng Suy, Nima Aghdam, Constantine Mantz, Alan J Katz, Leszek Miszczyk, Aleksandra Napieralska, Agnieszka Namysl-Kaletka, Nicholas Prionas, Hilary Bagshaw, Mark K Buyyounouski, Minsong Cao, Nzhde Agazaryan, Audrey Dang, Ye Yuan, Patrick A Kupelian, Nicholas G Zaorsky, Daniel E Spratt, Osama Mohamad, Felix Y Feng, Brandon A Mahal, Paul C Boutros, Arun U Kishan, Jesus Juarez, David Shabsovich, Tommy Jiang, Sartajdeep Kahlon, Ankur Patel, Jay Patel, Nicholas G Nickols, Michael L Steinberg, Donald B Fuller, Amar U Kishan
BACKGROUND AND PURPOSE: The optimal dose for prostate stereotactic body radiotherapy (SBRT) is still unknown. This study evaluated the dose-response relationships for prostate-specific antigen (PSA) decay and biochemical recurrence (BCR) among 4 SBRT dose regimens. MATERIALS AND METHODS: In 1908 men with low-risk (50.0%), favorable intermediate-risk (30.9%), and unfavorable intermediate-risk (19.1%) prostate cancer treated with prostate SBRT across 8 institutions from 2003 to 2018, we examined 4 regimens (35 Gy/5 fractions [35/5, n = 265, 13...
January 2021: Radiotherapy and Oncology